Last reviewed · How we verify

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium

Niels Van Regenmortel · FDA-approved active Small molecule

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium is a Intravenous fluid replacement / Electrolyte solution Small molecule drug developed by Niels Van Regenmortel. It is currently FDA-approved for Hypovolemia and dehydration requiring intravenous fluid replacement, Hypokalemia or potassium depletion prevention during fluid therapy, Maintenance of electrolyte and fluid balance in hospitalized patients.

This intravenous fluid replacement solution provides sodium chloride, glucose, and potassium to restore electrolyte balance and provide hydration and calories.

This intravenous fluid replacement solution provides sodium chloride, glucose, and potassium to restore electrolyte balance and provide hydration and calories. Used for Fluid and electrolyte replacement in dehydration, Maintenance therapy in patients unable to take oral intake, Hypokalemia correction.

At a glance

Generic nameNaCl 0.9% in Glucose 5% + 40mmol/L Potassium
SponsorNiels Van Regenmortel
Drug classIntravenous fluid replacement / Electrolyte solution
ModalitySmall molecule
Therapeutic areaCritical Care / Fluid and Electrolyte Management
PhaseFDA-approved

Mechanism of action

The formulation combines isotonic saline (0.9% NaCl) with 5% glucose to provide both electrolyte replacement and a modest caloric source, while the 40 mmol/L potassium supplementation addresses hypokalemia or prevents potassium depletion during fluid therapy. This is a standard parenteral nutrition/rehydration solution used to maintain or restore normal serum electrolyte concentrations and intravascular volume.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NaCl 0.9% in Glucose 5% + 40mmol/L Potassium

What is NaCl 0.9% in Glucose 5% + 40mmol/L Potassium?

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium is a Intravenous fluid replacement / Electrolyte solution drug developed by Niels Van Regenmortel, indicated for Hypovolemia and dehydration requiring intravenous fluid replacement, Hypokalemia or potassium depletion prevention during fluid therapy, Maintenance of electrolyte and fluid balance in hospitalized patients.

How does NaCl 0.9% in Glucose 5% + 40mmol/L Potassium work?

This intravenous fluid replacement solution provides sodium chloride, glucose, and potassium to restore electrolyte balance and provide hydration and calories.

What is NaCl 0.9% in Glucose 5% + 40mmol/L Potassium used for?

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium is indicated for Hypovolemia and dehydration requiring intravenous fluid replacement, Hypokalemia or potassium depletion prevention during fluid therapy, Maintenance of electrolyte and fluid balance in hospitalized patients.

Who makes NaCl 0.9% in Glucose 5% + 40mmol/L Potassium?

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium is developed and marketed by Niels Van Regenmortel (see full Niels Van Regenmortel pipeline at /company/niels-van-regenmortel).

What drug class is NaCl 0.9% in Glucose 5% + 40mmol/L Potassium in?

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium belongs to the Intravenous fluid replacement / Electrolyte solution class. See all Intravenous fluid replacement / Electrolyte solution drugs at /class/intravenous-fluid-replacement-electrolyte-solution.

What development phase is NaCl 0.9% in Glucose 5% + 40mmol/L Potassium in?

NaCl 0.9% in Glucose 5% + 40mmol/L Potassium is FDA-approved (marketed).

What are the side effects of NaCl 0.9% in Glucose 5% + 40mmol/L Potassium?

Common side effects of NaCl 0.9% in Glucose 5% + 40mmol/L Potassium include Hyperkalemia (if renal function impaired), Hyponatremia (with excessive administration), Phlebitis at infusion site, Hyperglycemia (in diabetic patients).

Related